BACKGROUND: Engineering of the antibody's fragment crystallizable (Fc) by modifying the amino acid sequence (Fc protein engineering) or the glycosylation pattern (Fc glyco-engineering) allows enhancing effector functions of tumor targeting antibodies. Here, we investigated whether complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20 antibodies could be improved simultaneously by combining Fc protein engineering and glyco-engineering technologies. METHODS AND RESULTS: Four variants of the CD20 antibody rituximab were generated: a native IgG1, a variant carrying the EFTAE modification (S267E/H268F/S324T/G236A/I332E) for enhanced CDC as well as glyco-engineered, non-fucosylated derivatives of both to boost ADCC. The antibodies bound CD20 specifically with similar affinity. Antibodies with EFTAE modification were more efficacious in mediating CDC, irrespective of fucosylation, than antibodies with wild-type sequences due to enhanced C1q binding. In contrast, non-fucosylated variants had an enhanced affinity to FcγRIIIA and improved ADCC activity. Importantly, the double-engineered antibody lacking fucose and carrying the EFTAE modification mediated both CDC and ADCC with higher efficacy than the native CD20 IgG1 antibody. CONCLUSION: Combining glyco-engineering and protein engineering technologies offers the opportunity to simultaneously enhance ADCC and CDC activities of therapeutic antibodies. This approach may represent an attractive strategy to further improve antibody therapy of cancer and deserves further evaluation.
BACKGROUND: Engineering of the antibody's fragment crystallizable (Fc) by modifying the amino acid sequence (Fc protein engineering) or the glycosylation pattern (Fc glyco-engineering) allows enhancing effector functions of tumor targeting antibodies. Here, we investigated whether complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20 antibodies could be improved simultaneously by combining Fc protein engineering and glyco-engineering technologies. METHODS AND RESULTS: Four variants of the CD20 antibody rituximab were generated: a native IgG1, a variant carrying the EFTAE modification (S267E/H268F/S324T/G236A/I332E) for enhanced CDC as well as glyco-engineered, non-fucosylated derivatives of both to boost ADCC. The antibodies bound CD20 specifically with similar affinity. Antibodies with EFTAE modification were more efficacious in mediating CDC, irrespective of fucosylation, than antibodies with wild-type sequences due to enhanced C1q binding. In contrast, non-fucosylated variants had an enhanced affinity to FcγRIIIA and improved ADCC activity. Importantly, the double-engineered antibody lacking fucose and carrying the EFTAE modification mediated both CDC and ADCC with higher efficacy than the native CD20 IgG1 antibody. CONCLUSION: Combining glyco-engineering and protein engineering technologies offers the opportunity to simultaneously enhance ADCC and CDC activities of therapeutic antibodies. This approach may represent an attractive strategy to further improve antibody therapy of cancer and deserves further evaluation.
Entities:
Keywords:
ADCC; Antibody therapy; CD20; CDC; Fc engineering
Authors: Annalina Tammen; Stefanie Derer; Ralf Schwanbeck; Thies Rösner; Anna Kretschmer; Frank J Beurskens; Janine Schuurman; Paul W H I Parren; Thomas Valerius Journal: J Immunol Date: 2017-01-06 Impact factor: 5.422
Authors: Roland Repp; Christian Kellner; Anja Muskulus; Matthias Staudinger; Sahar Mohseni Nodehi; Pia Glorius; Dalia Akramiene; Michael Dechant; Georg H Fey; Patrick H C van Berkel; Jan G J van de Winkel; Paul W H I Parren; Thomas Valerius; Martin Gramatzki; Matthias Peipp Journal: J Immunol Methods Date: 2011-08-09 Impact factor: 2.303
Authors: Rajat Bannerji; Shinichi Kitada; Ian W Flinn; Michael Pearson; Donn Young; John C Reed; John C Byrd Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: Mitchell Evers; Thies Rösner; Anna Dünkel; J H Marco Jansen; Niklas Baumann; Toine Ten Broeke; Maaike Nederend; Klara Eichholz; Katja Klausz; Karli Reiding; Denis M Schewe; Christian Kellner; Matthias Peipp; Jeanette H W Leusen; Thomas Valerius Journal: Blood Adv Date: 2021-10-12
Authors: Louise W Treffers; Michel van Houdt; Christine W Bruggeman; Marieke H Heineke; Xi Wen Zhao; Joris van der Heijden; Sietse Q Nagelkerke; Paul J J H Verkuijlen; Judy Geissler; Suzanne Lissenberg-Thunnissen; Thomas Valerius; Matthias Peipp; Katka Franke; Robin van Bruggen; Taco W Kuijpers; Marjolein van Egmond; Gestur Vidarsson; Hanke L Matlung; Timo K van den Berg Journal: Front Immunol Date: 2019-01-30 Impact factor: 7.561
Authors: David A Spencer; Benjamin S Goldberg; Shilpi Pandey; Tracy Ordonez; Jérémy Dufloo; Philip Barnette; William F Sutton; Heidi Henderson; Rebecca Agnor; Lina Gao; Timothée Bruel; Olivier Schwartz; Nancy L Haigwood; Margaret E Ackerman; Ann J Hessell Journal: Nat Commun Date: 2022-02-03 Impact factor: 17.694